Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
8.95
+0.07 (0.79%)
Dec 11, 2025, 4:00 PM EST - Market closed
Valneva SE Revenue
Valneva SE had revenue of 29.41M EUR in the quarter ending September 30, 2025, a decrease of -35.82%. This brings the company's revenue in the last twelve months to 179.91M, up 13.48% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
179.91M EUR
Revenue Growth
+13.48%
P/S Ratio
3.66
Revenue / Employee
252,331 EUR
Employees
713
Market Cap
772.67M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | 126.20M | 13.16M | 11.64% |
| Dec 31, 2018 | 113.04M | 7.74M | 7.35% |
| Dec 31, 2017 | 105.29M | 7.40M | 7.56% |
| Dec 31, 2016 | 97.89M | 14.56M | 17.47% |
| Dec 31, 2015 | 83.33M | 40.91M | 96.41% |
| Dec 31, 2014 | 42.43M | 6.44M | 17.89% |
| Dec 31, 2013 | 35.99M | 326.00K | 0.91% |
| Dec 31, 2012 | 35.67M | 2.78M | 8.46% |
| Dec 31, 2011 | 32.88M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VALN News
- 1 day ago - Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 6 days ago - VALNEVA Declaration of shares and voting rights: November 30, 2025 - GlobeNewsWire
- 15 days ago - Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings - Benzinga
- 15 days ago - Valneva to Further Consolidate its Operations in France - GlobeNewsWire
- 15 days ago - Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study - WSJ
- 15 days ago - Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate - GlobeNewsWire
- 21 days ago - Valneva SE (VALN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire